J&J Forecasts Quicker EU Conversion To Cypher In Wake Of FDA Sign-Off
This article was originally published in The Gray Sheet
Executive Summary
U.S. approval of Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent will exert pressure on key European markets to pay for the device despite its significant price premium over conventional coronary stents, the company asserts
You may also be interested in...
Boston Scientific Narrowing Gap With J&J In European DES Market
Boston Scientific's Taxus stent is on track to claim half of the European drug-eluting stent market from rival and first-mover Johnson & Johnson/Cordis over the next several months, the firm says
Boston Scientific Narrowing Gap With J&J In European DES Market
Boston Scientific's Taxus stent is on track to claim half of the European drug-eluting stent market from rival and first-mover Johnson & Johnson/Cordis over the next several months, the firm says
J&J Says 30,000-40,000 Patients Are On Standby For Cypher Approval
Interventional cardiologists are delaying a significant number of conventional stenting procedures as they anticipate near-term FDA approval of Johnson & Johnson's sirolimus-eluting Cypher stent